| CAS: | 1225278-16-9 | |
| 分子式: | C26H21F2N5O3 | |
| 分子量: | 489.47 | |
| 英文名称: |
| |
| 用途: | 是一种有效的 c-Kit 和 c-Met 抑制剂，IC50 值 <200 nM。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||
| K795822 | MACKLIN | c-Kit-IN-1 | 10mM in DMSO | 706元/1ml; | 展开 | ||||||||||||||||||||||||||||||
储存：-20°C | |||||||||||||||||||||||||||||||||||
| D861073 | MACKLIN | c-Kit-IN-1 | >98% | 128元/5mg; 199元/10mg; 376元/50mg; 750元/100mg; | 展开 | ||||||||||||||||||||||||||||||
储存：-20℃ 状态：白色固体 折射率：white solid | |||||||||||||||||||||||||||||||||||
| SML2875 | Sigma-Aldrich | DCC-2618 | ≥98% (HPLC) | 833.87元/5 MG; 3365.56元/25 MG; | 展开 | ||||||||||||||||||||||||||||||
产品说明 生化/生理作用 DCC-2618 is an orally active, potent type II switch pocket (SP) inhibitor against c-KIT (IC50 = 4 nM/WT, 8 nM/V654A, 18 nM/T670I, 5 nM/D816H, 14 nM/D816V) and PDGFR. DCC-2618 locks c-KIT & PDGFR in an inactive conformation and is effective against multiple clinical forms of mutations resistant to type I ATP (catalytic)-site inhibitors Imatinib and Sunitinib. DCC-2618 inhibits cellular c-KIT activation (IC50 = 36 nM/WT, 2 nM/ex 11 del, 7 nM/ex 11 del & V654A, 53 nM/V560D & D820A) and is efficacious against KIT mutants-mediated cancer growth in cultres (IC50 = 2 nM; GIST with KIT D816Y) and in mice in vivo (50 mg/kg b.i.d. p.o.; GIST with KIT delW557K558/Y823D, AML with KIT N822K). 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||
m.cnreagent.com